FDA approves reformulated vonoprazan for H. pylori; launch expected Dec 2023

Phathom Pharmaceuticals, Inc.

FDA approved prior approval supplements for reformulated vonoprazan tablets in VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for H. pylori infection in adults.
Product expected to be available in the U.S. in December 2023 and marketed exclusively by Phathom.
H. pylori infects an estimated 115 million individuals in the U.S.; 36% of the U.S. population estimated to be infected.
Phathom planning combined U.S. commercial launch of H. pylori regimens and Erosive GERD vonoprazan, if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.